Penederm, Mylan Laboratories Inc. deal

Mylan, a developer of generic pharmaceuticals delivered orally and via transdermal patches, will acquire DERM in a stock deal worth $205 million based on Mylan's closing price prior to the announcement. Mylan will issue 0.68 shares for each DERM share. Mylan has 123 million shares outstanding, and DERM has 9.3 million shares outstanding. ...